pubs.acs.org/joc
and modify its biological activity. Accordingly, some apparently
Synthesis of Chlorinated Bicyclic C-Fused
Tetrahydrofuro[3,2-c]azetidin-2-ones
otherwise nonactivated monocyclic N-aryl-R-chloro-β-lactams3
have been reported to exhibit promising antibacterial,3a-e anti-
fungal,3a-e and antitubercular3e activities and activities against
nonmicrobial diseases such as antitumor,1a anticonvulsant,3f
anti-Parkinson,3f CNS,3f and HLE inhibitory activities.3g Some
6-chloropenams possess β-lactamase inhibitory activities4 and
7-chlorocephems display anticancer5 and HLE- and PPE-
inhibitory1a activities.
Ram N. Ram,* Neeraj Kumar, and Nem Singh†
Department of Chemistry, Indian Institute of Technology,
Delhi, Hauz Khas, New Delhi 110016, India. †Contributed to
the analysis of crystallographic data.
3,4-Fused (C-fused) bicyclic β-lactams, in which the lac-
tam nitrogen is not pyramidal, are apparently nonactivated
and have received much less attention6 as compared to their
celebrated N-fused analogues. They have rather been used as
intermediates for the synthesis of the N-fused bicyclic
β-lactams.7 However, some activated β-lactams C-fused with
a cyclopentene,8a pyrrolidine,8b,c or thiazolidine7b ring were
found to possess promising β-lactamase inhibitory activities,
and recently, some otherwise additionally nonactivated bi-
cyclic β-lactams C-fused with carbocycles and a sugar unit9
have been reported to exhibit promising nonclassical biolo-
gical activities against malaria,9a leishmaniasis,9b and several
types of cancer.9c Moreover, new applications in the synthe-
sis of non-β-lactam molecules of biological significance
have also been discovered.6a,10 Although the tetrahydro-
furan structural unit is abundant in bioactive natural and
Received June 3, 2010
Some bicyclic C-fused chlorinated tetrahydrofuro[3,2-c]aze-
tidin-2-ones were prepared by a fairly general route involving
Staudinger reaction of allylic/propargylic imidates with di-
chloroketene followed by highly diastereoselective CuCl/
PMDETA-catalyzed 5-exo-trig/dig chlorine atom transfer
radical cyclization. An oxepan-fused β-lactam was also pre-
pared similarly by 7-endo-trig cyclization. Synthetic applica-
tion of the side chain chlorine atom of the products was
demonstrated by its substitution in one of the products with
azide followed by azide-alkyne click reaction with phenyla-
cetylene to obtain a 1,2,3-triazolyltetrahydrofuro[3,2-c]aze-
tidin-2-one.
(4) Knowle, J. R. Acc. Chem. Res. 1985, 18, 97.
(5) Vorona, M.; Veinberg, G.; Shestakova, I.; Kanepe, I.; Petrova, M.;
Liepinsh, E.; Lukevics, E. Chem. Heterocycl. Compd. 2007, 43, 1567.
(6) Reviews: (a) Alcaide, B.; Almendros, P. Curr. Med. Chem. 2004, 11,
1921. (b) Alcaide, B.; Almendros, P. Curr. Org. Chem. 2002, 6, 245. (c)
Gomez-Gallego, M.; Mancheno, M. J.; Sierra, M. A. Tetrahedron 2000, 56,
5743. Some other references: (d) Zhang, Z.; Zhang, Q.; Ni, Z.; Liu, Q. Chem.
Commun. 2010, 46, 1269 and references cited therein. (e) Alcaide, B.;
Almendros, P.; del Campo, T. M.; Soriano, E.; Marco-Contelles, J. L.
Chem.;Eur. J. 2009, 15, 1901. (f) Alcaide, B.; Almendros, P.; del Campo,
T. M. Angew. Chem., Int. Ed. 2007, 46, 6684. (g) Alcaide, B.; Almendros, P.;
Rodriguez-Acebes, R. Synthesis 2005, 2335. (h) Alcaide, B.; Almendros, P.;
Aragoncillo, C. Org. Lett. 2003, 5, 3795. (i) Alcaide, B.; Almendros, P.; Luna,
A.; del Campo, T. M. J. Org. Chem. 2008, 73, 1635. (j) He, M.; Bode, J. W. J.
Am. Chem. Soc. 2008, 130, 418. (k) Alcaide, B.; Almendros, P.; Aragoncillo,
C.; Redondo, M. C.; Torres, M. R. Chem.;Eur. J. 2006, 12, 1539. (l)
Alcaide, B.; Almendros, P.; Rodrıguez-Acebes, R. J. Org. Chem. 2005, 70,
2713.
The well-known antibacterial and most of the nonantibac-
terial1 activities of β-lactams rest on some additional activation
of the β-lactam ring toward nucleophilic enzymatic ring-open-
ing. This additional activation is brought in by a pyramidal
lactam nitrogen through 1,4-fusion (N-fusion) with another
ring, electron-withdrawing (-R or -I) N-substituent, and/or a
nucleofugal group.1 A chlorine substituent at the R position of
the β-lactam ring is expected to increase its chemical reactivity2
_
(7) (a) Review: Łysek, R.; Borsuk, K.; Furman, B.; Kazuza, Z.;
Kazimierski, A.; Chmielewski, M. Curr. Med. Chem. 2004, 11, 1813. (b) Ren
X.-F.; Konaklieva, M. I.; Shi, H.; Dickey, S.; Lim, D. V.; Gonzalez, J.; Turos,
E. J. Org. Chem. 1998, 63, 8898.
(8) (a) Singh, R.; Cooper, R. D. G. Tetrahedron 1994, 50, 12049. (b)
Heinze-Krauss, I.; Angehrn, P.; Charnas, R. L.; Gubernator, K.; Gutknecht,
E.-M.; Hubschwerlen, C.; Kania, M.; Oefner, C.; Page, M. G. P.; Sogabe, S.;
Specklin, J.-L.; Winkler, F. J. Med. Chem. 1998, 41, 3961. (c) Hubschwerlen,
C.; Charnas, R.; Heinze, I.; Gubernator, K. US Patent US 6,566,355 B1,
2003.
(9) (a) Nivsarkar, M.; Thavaselvam, D.; Prasanna, S.; Sharma, M.;
Kaushik, M. P. Bioorg. Med. Chem. Lett. 2005, 15, 1371. (b) Ruhela, D.;
Chatterjee, P.; Vishwakarma, R. A. Org. Biomol. Chem. 2005, 3, 1043. (c)
Hogan, P. C.; Corey, E. J. J. Am. Chem. Soc. 2005, 127, 15386. It appears
that additional activation of the β-lactam ring may not be absolutely essential
for its biological activity, particularly with regard to the biological activities
other than antibacteria.l (d) Kvrn, L.; Werder, M.; Hauser, H.; Carreira,
E. M. J. Med. Chem. 2005, 48, 6035.
(1) Reviews: (a) Veinberg, G.; Vorona, M.; Shestakova, I.; Kanepe, I.;
Lukevics, E. Curr. Med. Chem. 2003, 10, 1741. (b) Powers, J. C.; Asgian, J. L.;
Ekici, O. D.; James, K. E. Chem. Rev. 2002, 102, 4639.
(2) Joyeau, R.; Molines, H.; Labia, R.; Wakselman, M. J. Med. Chem.
1988, 31, 370.
(3) (a) Jubie, S.; Gowramma, B.; Muthal, N. K.; Kalirajan, R.; Gomathi,
S.; Elango, K. Int. J. Chem. Tech. Res. 2009, 2, 153. (b) Halve, A. K.;
Bhadauria, D.; Dubey, R. Bioorg. Med. Chem. Lett. 2007, 17, 341. (c) Guner,
V.; Yıldırır, S.; Ozcelık, B.; Abbasoglu, U. Farmaco 2000, 55, 147. (d)
Khalafallah, A. K.; Selim, M. A.; Abu El-hamd, R. M.; Elmaghraby,
M. A.; Soleiman, H. A.; Raslan, M. A. Indian J. Chem. 1995, 34B, 1066.
(e) Vashi, B. S.; Mehta, D. S.; Shah, V. H. Indian J. Chem. 1995, 34B, 802. (f)
Refs. cited in Goel, R. K.; Singh, A.; Naidu, P. S.; Mahajan, M. P.; Kulkarni,
S. K. J. Pharm. Pharm. Sci. 2005, 8, 182. (g) Vergely, I.; Boggetto, N.;
Okochi, V.; Golpayegani, S.; Reboud-Ravaux, M.; Kobaiter, R.; Joyeau, R.;
Wakselman, M. Eur. J. Med. Chem. 1995, 30, 199.
(10) (a) Alcaide, B.; Almendros, P.; Aragoncillo, C. Chem. Rev. 2007, 107,
€ €
4437. (b) Fulop, F Chem. Rev. 2001, 101, 2181. (c) Leemans, E.; D’hooghe,
€
M.; Dejaegher, Y.; Tornroos, K. W.; De Kimpe, N. Eur. J. Org. Chem. 2010,
ꢀ
€ €
352. (d) Kazi, B.; Kiss, L.; Forro, E.; Fulop, F. Tetrahedron Lett. 2010, 51, 82.
(e) Zhang, J.; Kissounko, D. A.; Lee, S. E.; Gellman, S. H.; Stahl, S. S. J. Am.
Chem. Soc. 2009, 131, 1589. (f) Yang, Y.; Wang, F.; Rochon, F. D.; Kayser,
M. M. Can. J. Chem. 2005, 83, 28.
7408 J. Org. Chem. 2010, 75, 7408–7411
Published on Web 09/27/2010
DOI: 10.1021/jo101045z
r
2010 American Chemical Society